ALRN

Aileron Therapeutics, Inc. (ALRN) | Rumor.io

Aileron Therapeutics

ALRN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ALRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 1

Aileron Therapeutics (ALRN) announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF), showing a positive trend in 7 of 8 IPF biomarkers.
The company priced an underwritten registered direct offering of up to approximately $40 million, with an initial funding of around $20 million and potential for additional proceeds.
ALRN's share price was impacted by the news, with some traders expressing optimism about the company's prospects and potential for a merger and acquisition (M&A) deal.

Generated by AI

Sentiment

Of the messages about ALRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.47% +12.91
Bearish	—	—	—	10.53% -12.91

Bullish· Dec 14

Aileron Therapeutics, Inc. ($ALRN) has shown significant price movement, increasing by 70% with no news, similar to another low-float biotech ($PULM).
The company's stock has broken above a key level, with a target of $8 if it surpasses $5, and is showing signs of a further gap up.
$ALRN has a low float of 3.5M and a short float of 2.2%, indicating a potential for continued price appreciation.

Bearish· Jan 5

Aileron Therapeutics, Inc. ($ALRN) has seen a significant price drop of 40% in an hour with no bounce.
The company's share price was smashed down to less than $1.40, facilitated by a firm that managed the ATM offering.
Shorting $ALRN at $2.05 may be a good opportunity, as the stock has already dropped 100% in pre-market trading with no news.

Generated by AI

Topics

Of the messages about ALRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	14.29%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	85.71%
Analysts	—	—	—	0%

Analysts· Jul 24

Aileron Therapeutics, Inc. (ALRN) was initiated with a Buy rating by BofA/Merrill Lynch and Jefferies, with price targets of $19 and $20, respectively.
William Blair initiated coverage on ALRN with an Outperform rating.
Several analysts, including Bank of America Corporation, Jefferies Group LLC, and Canaccord Genuity, initiated coverage on ALRN with Buy or Outperform ratings.

Announcements· Feb 21

Aileron Therapeutics (ALRN) has terminated its Phase 1b breast cancer chemoprotection trial due to unfavorable findings.
The company is exploring strategic alternatives, including reducing its workforce to 3 full-time employees and retaining the remaining employees to assist in the review process.
ALRN shares are trading lower after the announcement, with a significant price decline of 39.1% pre-market.

Generated by AI

Community

Of the messages about ALRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	48.84%
Newcomers	—	—	—	51.16%

Regulars· Feb 21

Aileron Therapeutics has terminated its Phase 1b breast cancer chemoprotection trial and is exploring strategic alternatives, citing setbacks for its cancer candidate.
The company's stock is down 39% on the news, with some analysts noting a significant decline in the company's workforce from 9 to 3 full-time employees.
Aileron's remaining workforce will assist in executing the strategic alternatives review process, and the company will retain its remaining employees to support this effort.

Newcomers· Dec 15

The asset's price has increased from $1 in November 2023 to $4, with a significant volume of trades in a short period.
The company's third-quarter revenue and EPS fell short of analyst estimates, leading to a decline in the asset's value.
The asset's price rose significantly in pre-market trading after positive results from a Phase 1 trial, indicating potential for further growth.

Generated by AI

Also Discussed

Investors talking about ALRN also mention

#	Name	Attention
1	GTHX - G1 Therapeutics, Inc.	——
2	Maiden Holdings Ltd.MHLD	0%0
3	ASLN - ASLAN Pharmaceuticals Limited	——
4	Xenetic Biosciences, Inc.XBIO	0%new
5	Ovid Therapeutics Inc.OVID	0%0
6	Viveve Medical Inc.VIVE	0%0
7	Lipocine Inc.LPCN	0%new
8	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
9	Milestone Scientific Inc.MLSS	0%+0
10	ARC - ARC Document Solutions, Inc.	——